JPMorgan ups Ideaya target, adds to Analyst Focus List

JPMorgan raised the firm’s price target on Ideaya Biosciences to $51 from $41 and keeps an Overweight rating on the shares. The analyst also added the shares to the firm’s Analyst Focus List. The company was enthusiastic on the potential of darovasertib in the neoadjuvant uveal melanoma setting, with data anticipated mid-2024, the analyst tells investors in a research note. The firm says the known darovasertib data is encouraging, thus de-risking the mid-year update.